UK grants patients early access to IONIS APOC IIIRx for familial chylomicronaemia syndrome.- Akcea Therapeutics.
The Medicines and Healthcare products Regulatory Agency has announced that IONIS APOC IIIRx (volanesorsen), from Akcea Therapeutics, will be available to eligible patients for the treatment of familial chylomicronaemia syndrome (FCS) in the UK before it is officially licensed in the EU, having been granted entry to the country�s Early Access to Medicines Scheme.
Comment: FCS is a severe, rare disorder characterized by extremely high levels of triglycerides, symptoms such as extreme abdominal pain that affect daily living, and the risk of recurrent, potentially fatal, acute pancreatitis. FCS impacts people across the globe.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins